ARYD

ARYA Sciences Acquisition Corp IV (ARYD) | Rumor.io

ARYA Sciences Acquisition IV

ARYD

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio188.2

Market capitalization1.5M

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-2.1M

Social

What share of all stock conversation is about ARYD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 24

ARYA Sciences Acquisition Corp IV (ARYD) and Amicus Therapeutics have mutually terminated their business combination agreement due to unfavorable market conditions.
The termination is attributed to challenging environments for stand-alone gene therapy companies and unfavorable market conditions affecting IPOs, follow-on financings, and SPACs in the biotech sector.
The deal's termination will result in a delay of clinical advancement for multiple gene therapies and a $400M cut in R&D and pipeline activities.

Generated by AI

Sentiment

Of the messages about ARYD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Topics

Of the messages about ARYD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Feb 24

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics have mutually agreed to terminate their planned business combination agreement due to unfavorable market conditions.
The termination of the agreement is attributed to a challenging environment for stand-alone gene therapy companies, affecting IPOs, follow-on financings, and SPACs in the biotech sector.
The deal's termination will result in a delay of clinical advancement for multiple gene therapies and a 7% reduction in force (RIF) and hiring freeze at Amicus Therapeutics.

Generated by AI

Community

Of the messages about ARYD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	—
Newcomers	—	—	—	—

Also Discussed

Investors talking about ARYD also mention

#	Name	Attention
1	ARYE - ARYA Sciences Acquisition Corp V	——
2	AMC Robotics CorporationAMCI	0%0
3	LDHA - LDH Growth Corp I	——
4	ATAQ - Altimar Acquisition Corp. III	——
5	ARRW - Arrowroot Acquisition Corp.	——
6	LSAQ - LifeSci Acquisition II Corp.	——
7	HYAC - Haymaker Acquisition Corp. III	——
8	BCTG - BCTG Acquisition Corp.	——
9	GHVI - Gores Holdings VI, Inc.	——
10	ROCR - Roth CH Acquisition III Co.	——

ARYA Sciences Acquisition Corp IV

Financial Services
Shell Companies

Arya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.

Website

Location

51 Astor Place

New York, NY, 10003

United States

Social

What share of all stock conversation is about ARYD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 24

ARYA Sciences Acquisition Corp IV (ARYD) and Amicus Therapeutics have mutually terminated their business combination agreement due to unfavorable market conditions.
The termination is attributed to challenging environments for stand-alone gene therapy companies and unfavorable market conditions affecting IPOs, follow-on financings, and SPACs in the biotech sector.
The deal's termination will result in a delay of clinical advancement for multiple gene therapies and a $400M cut in R&D and pipeline activities.

Generated by AI

Sentiment

Of the messages about ARYD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Topics

Of the messages about ARYD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Feb 24

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics have mutually agreed to terminate their planned business combination agreement due to unfavorable market conditions.
The termination of the agreement is attributed to a challenging environment for stand-alone gene therapy companies, affecting IPOs, follow-on financings, and SPACs in the biotech sector.
The deal's termination will result in a delay of clinical advancement for multiple gene therapies and a 7% reduction in force (RIF) and hiring freeze at Amicus Therapeutics.

Generated by AI

Community

Of the messages about ARYD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	—
Newcomers	—	—	—	—

ARYA Sciences Acquisition IV

Social

Feb 24

Sentiment

Topics

Feb 24

Community

Also Discussed

ARYA Sciences Acquisition Corp IV

Company Information

Location

Also Discussed

Social

Feb 24

Sentiment

Topics

Feb 24

Community